Email this article Use of a nonselective endothelin receptor antagonist in idiopathic pulmonary hypertension
- Authors: Arkhipova O.A.1, Martynyuk T.V.1, Lazutkina V.K.1, Ataullakhanova D.M.1, Stukalova O.V.1, Danilov N.M.1, Samoylenko L.E.1, Chazova I.E.1, Arkhipova OA2, Martynyuk TV2, Lazutkina VK2, Ataullakhanova DM2, Stukalova OV2, Danilov NM2, Samoilenko LE2, Chazova IE2
-
Affiliations:
- Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
- Issue: Vol 82, No 11 (2010)
- Pages: 70-73
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30759
- ID: 30759
Cite item
Full Text
Abstract
Endothelin receptor antagonists (ERA) are one of the effective classes of drugs for the treatment of patients with IPH. Bosentan is the first drug from the ERA class that blocks the receptors of both types and that has been recommended by the WHO to treat patients with functional class II-IV pulmonary hypertension.
The described case demonstrates the possibility of concomitantly using bosentan in a female patient with IPH shortly after ineffective treatment with a calcium antagonist.
About the authors
Ol'ga Aleksandrovna Arkhipova
Tamila Vital'evna Martynyuk
Valentina Kirillovna Lazutkina
Dil'bar Mukumovna Ataullakhanova
Ol'ga Vladimirovna Stukalova
Nikolay Mikhaylovich Danilov
Lyudmila Evgen'evna Samoylenko
Irina Evgen'evna Chazova
O A Arkhipova
Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesRussian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
T V Martynyuk
Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesRussian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
V K Lazutkina
Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesRussian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
D M Ataullakhanova
Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesRussian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
O V Stukalova
Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesRussian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
N M Danilov
Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesRussian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
L E Samoilenko
Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesRussian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
I E Chazova
Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesRussian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
References
- Беленков Ю. Н., Чазова И. Е. Первичная легочная гипертензия. М.: Нолидж; 1999.
- D'Alonzo G. E., Barst R. J., Ayres S. M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115: 343-349.
- Диагностика и лечение легочной гипертензии: Российские рекомендации ВНОК. М.; 2007.
- Мартынюк Т. В., Масенко В. П., Чазова И. Е. и др. Эндотелиальная дисфункция у больных с легочной гипертензией. Кардиология 1997; 10: 25-29.
- Lopes A. A., Maeda N. Y., Gongalves R. C., Bydlowski S. P. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am. Heart J. 2000; 139 (4): 618-623.
- Guidelines for the diagnosis and treatment of pulmonary hypertension. Update 2009. European society of cardiology. Eur. Heart J. 2009; 30: 2493-2537.
- Rubin L. J., Badesch D. B., Barst R. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002; 346 (12): 896-903.
- Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2004; 351: 1425-1436.
- Clozel M. Endothelin receptor antagonists: current status and perspectives. J. Cardiovasc. Pharmacol. 2000; 35: S65.
- Channick R. N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with primary hypertension: a randomized placebo-controlled study. Lancet 2001; 358: 1119-1123.
Supplementary files
